Trial of Adjuvant Chemotherapy for Gastric Cancer

Stomach Cancer Clinical Trial

Official title:

A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Gastric Adenocarcinoma: Mitomycin and Doxifluridine Versus Intraperitoneal Chemotherapy and Mitomycin, Doxifluridine, and Cisplatin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00296322
• Other study ID #: AMC0102
• Status: Completed
• Phase: Phase 3
• Start date: October 2001
• Est. completion date: March 2010

Study information

• Verified date: January 2020
• Source: Asan Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to evaluate the efficacy of the intraperitoneal chemotherapy with early mitomycin administration and adding cisplatin to prolonged treatment with doxifluridine compared to mitomycin plus doxifluridine in resected advanced gastric cancer.

Description:

Stomach cancer is the most common cancer in Korea and one of the major health problems worldwide. The most effective treatment for gastric cancer is curative surgical resection of primary tumor. However, a substantial number of patients eventually die of recurrences after curative resection. A number of randomized trials investigating the role of adjuvant chemotherapy have been conducted. However, the efficacy of adjuvant chemotherapy is still controversial and varied between Western and Asian trials. Meta-analysis of Western trials didn't demonstrate the benefit of adjuvant chemotherapy after curative resection. Conversely, some Asian studies have demonstrated the efficacy of adjuvant chemotherapy after curative resection. In a previous study, mitomycin plus tegafur prolonged the survival in resected gastric cancer compared to no treatment.

This study is designed to evaluate the efficacy of the intraperitoneal chemotherapy with early mitomycin administration and adding cisplatin to prolonged treatment with doxifluridine compared to mitomycin plus doxifluridine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 528
• Est. completion date: March 2010
• Est. primary completion date: December 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 69 Years

Eligibility

Inclusion Criteria:

• Pathologically proven gastric adenocarcinoma

• Grossly serosa invasion of primary tumor is suspicious

• Curative resection was done

• Stage II, IIIA, IIIB, IV (including T4, lesions or N3, but excluding M1 lymph node metastasis)

• Age: 18-69 years old

• Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2

• Adequate bone marrow function (white blood cell counts = 4,000/ul, platelet count = 100,000/ul, hemoglobin = 10 g/dl)

• Adequate renal function (serum creatinine= 1.5)

• Adequate liver function (serum bilirubin =1.5 mg/dl, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) = 3 x normal upper limit)

• Written informed consent was signed by the patient

Exclusion Criteria:

• Previous chemotherapy or radiotherapy

• Active ongoing infection which antibiotic treatment is needed

• Pregnant or lactating women

• Psychosis or convulsion disorder

• Ascites in preoperative abdomen computed tomography (CT)

• Systemic disease which interfere the administration of chemotherapy

• Postoperative pathologic stage IA, IB

• Postoperative pathology indicates that resection margin is involved

• Previous history of other malignancy except cured non-malignant skin cancer and uterine cervical cancer in situ

Related Conditions & MeSH terms

• Stomach Cancer
• Stomach Neoplasms

Intervention

Drug:
• cisplatin, mitomycin-C, doxifluridine
Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery) iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)

Locations

Country	Name	City	State
Korea, Republic of	Asan Medical Center	Seoul

Sponsors (3)

Lead Sponsor	Collaborator
Asan Medical Center	Hallym University Medical Center, Ulsan University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relapse-free Survival		3 years
Secondary	Toxicity Profile (According to NCI CTC Version 2.0)	Because safety profile in oncology study is evaluated for each toxicity, it is impossible to present the overall patient number. Instead, we presented the number of patients who declined study therapy due to adverse events or patient will.	up to 1 year
Secondary	Overall Survival		3 years